Cerebrolysin Sirop is a neuropeptide complex extracted from pig brain tissue using a standardized enzymatic hydrolysis process. Its active ingredients consist of 80% low molecular weight peptides (molecular weight<10kDa) and 20% free amino acids. This combination simulates the functions of natural neurotrophic factors such as BDNF and NGF, which have neuroprotective, neurotrophic, and promoting neural repair effects. Due to the significant influence of temperature, pH value, and light on the stability of peptide substances, their formulation design should avoid high-temperature sterilization or strong acid and alkali environments to prevent peptide chain breakage or amino acid degradation. Low molecular weight peptides require specific dosage forms (such as injections, enteric coated capsules) to achieve blood-brain barrier penetration. The raw materials from pig brain tissue need to be thoroughly removed of proteins, lipids, and endotoxins to reduce immunogenicity. This substance is also a liquid preparation containing high concentrations of sucrose or other sweeteners, commonly used to mask the bitterness of drugs or improve the medication experience for children/elderly people.
Our products
|
|
|
|
|
Cerebrolysin COA
Cell specific uptake and cargo release of Cerebrolysin Sirop
Peptide drugs have unique advantages in penetrating the blood-brain barrier (BBB) and targeted delivery due to their small molecular weight and flexible structure. However, their poor stability and susceptibility to enzymatic hydrolysis limit the development of oral formulations. Cerebrolysin, as a peptide mixture prepared by pig brain protease hydrolysis, contains a low molecular weight peptide segment (<10kDa) with a structure similar to endogenous neurotrophic factors such as BDNF and NGF. It can bind to neuronal Trk receptors through the BBB, activate Ras MAPK and PI3K Akt signaling pathways, promote synapse formation and neurotransmitter synthesis. However, currently the main dosage form of Cerebrolysin is injection, and the cellular uptake and release mechanism of the oral syrup dosage form (Cerebrolysin Sirop) is not yet clear.
Molecular basis of cell specific uptake: receptor-mediated targeted recognition
Specific binding of Trk receptor family
The core component of Cerebrolysin contains peptide segments highly homologous to BDNF, which can mimic the function of endogenous neurotrophic factors and initiate signal transduction by binding to TrkB receptors on the surface of neurons. Experiments have shown that peripheral injection of Cerebrolysin can induce the transformation of microglia into M2 type (anti-inflammatory phenotype) and reduce IL-6 secretion, which depends on the activation of the PI3K Akt pathway mediated by TrkB receptors. At the cellular uptake level, TrkB receptors internalize Cerebrolysin peptide segments into early endosomes through clathrin mediated endocytosis, followed by Rab5/Rab7 conversion for transport to late endosomes, and ultimately released into the cytoplasm.
Synergistic effects of low-density lipoprotein receptor (LRP)
In addition to Trk receptors, certain peptide segments in Cerebrolysin may be transported across membranes through the LRP family (such as LRP1, LRP2). LRP1 is highly expressed in BBB endothelial cells and neurons, capable of recognizing apolipoprotein E (ApoE) modified nanoparticles and promoting drug delivery through receptor-mediated endocytosis. In the potential mechanism of Cerebrolysin Sirop, if its peptide segment has structural similarity with ApoE, it may achieve blood-brain barrier penetration and neuronal targeted uptake through LRP1. For example, in the Alzheimer's disease model, there is a synergistic effect between LRP1 mediated clearance of A β and delivery of neurotrophic factors, suggesting that Cerebrolysin may optimize brain distribution through a similar mechanism.
Concentration dependence of cellular uptake
Cell uptake experiments showed that the uptake efficiency of Cerebrolysin significantly increased with increasing drug concentration, but there was a saturation threshold. In the high concentration group (>50 μ g/mL), the increase in cellular uptake tended to flatten out, which may be related to receptor saturation or overload of endocytic pathways. In addition, uptake efficiency is influenced by cell type: neuronal like cells (such as SH-SY5Y) have significantly higher uptake than non neuronal cells (such as HeLa), further supporting their receptor-mediated specificity.
Transmembrane transport mechanism: dynamic regulation from endocytosis to release
Clathrin mediated endocytosis (CME)
CME is the main pathway for uptake by Cerebrolysin cells. After TrkB receptor binds to the ligand, it recruits clathrin through the adaptive protein AP-2 to form drug encapsulated vesicles. Experiments have shown that inhibiting CME (such as using chlorpromazine) can significantly reduce the cellular uptake of Cerebrolysin, while inhibiting caveolin mediated endocytosis (CavME) has no significant effect, further confirming the dominant role of CME. After endocytosis, the vesicles fuse with early endosomes and regulate membrane fusion and cargo sorting through Rab5 GTPase.
Intracellular escape and cytoplasmic release
Internal escape is a key step in the efficacy of Cerebrolysin. Low molecular weight peptide segments can disrupt the endosome membrane through the "proton sponge effect": endosome acidification (pH<6) triggers peptide protonation, leading to the influx of chloride ions and water molecules, ultimately causing swelling and rupture of the endosome. In addition, certain peptide segments rich in hydrophobic amino acids may be directly inserted into the endosomal membrane, forming pores to promote release. The Cerebrolysin peptide segment released into the cytoplasm can freely diffuse to the perineum and interact with downstream signaling molecules of TrkB receptors (such as Shc and PLC γ), activating neuroprotective pathways.
Cross blood-brain barrier transport model
In the blood-brain barrier model, the transport efficiency of Cerebrolysin is influenced by the expression of tight junction proteins such as occludin and claudin-5. Experiments have shown that Cerebrolysin can stabilize the tight junctions of BBB endothelial cells and reduce the increase in endothelial permeability caused by rtPA thrombolytic therapy. This mechanism may be achieved through the following ways:
Inhibition of matrix metalloproteinase (MMP) activity: Cerebrolysin downregulates MMP-9 expression, reduces extracellular matrix degradation, and thus maintains BBB integrity.
Promote tight junction protein synthesis: By activating the PI3K Akt pathway, upregulate the transcription levels of occludin and ZO-1, and enhance the strength of intercellular connections.
Regulating endothelial cell metabolism: increasing glucose uptake and oxidative phosphorylation, improving energy supply, and supporting BBB function.
Cargo Release Dynamics: Time Dose Dependent Effects
The cargo release of Cerebrolysin exhibits a biphasic characteristic of rapid initial release (<2 hours) and sustained sustained release (2-24 hours). The initial release originates from the free peptide segments adsorbed on the cell membrane surface, while the sustained release stage relies on the gradual release of endocytic vesicles. In the SH-SY5Y cell model, after treatment with 50 μ g/mL Cerebrolysin, the intracellular peptide concentration reached its peak within 1 hour (Cmax ≈ 12 μ M), and then decreased at a rate of half-life (t1/2) ≈ 6 hours, suggesting that it can reduce the frequency of administration by prolonging the action time.
High doses of Cerebrolysin (>100 μ g/mL) may cause receptor desensitization: sustained activation of TrkB receptors leads to recruitment of β - arrestin, internalization of receptors into lysosomes for degradation, thereby reducing cell surface receptor density. This mechanism has also been demonstrated in clinical studies: daily intravenous injection of 30mL of Cerebrolysin (containing approximately 6.45g peptide segment) has good tolerability, but increasing the dose to 50mL did not significantly improve efficacy and may instead increase the risk of adverse reactions such as indigestion.
Extracellular pH, ionic strength, and enzyme activity significantly affect the release efficiency of Cerebrolysin. In the inflammatory microenvironment (such as the intestine of IBS patients), a decrease in local pH (<6.5) and an increase in protease activity (such as trypsin and chymotrypsin) may accelerate peptide degradation and reduce bioavailability. To optimize delivery efficiency, future formulation development needs to consider:
PH sensitive carrier: using poly (lactic acid glycolic acid) copolymer (PLGA) nanoparticles to encapsulate Cerebrolysin and release it stably in an alkaline intestinal environment.
Enzyme inhibitor combination: Used in combination with protease inhibitors such as metoclopramide to reduce gastrointestinal degradation.
Targeted modification: Extending circulation time through polyethylene glycol (PEG) functionalization or coupling with intestinal specific ligands (such as vitamin B12) to enhance absorption.
Clinical application prospects and challenges
Potential in digestive affective axis related diseases
Cerebrolysin may indirectly regulate the digestive affective axis through the following pathways:
Improving gut microbiota neurotransmitter axis: Enhancing the synergistic effect of SCFA on neurogenesis by upregulating BDNF expression, alleviating visceral hypersensitivity in FGIDs patients.
Inhibiting neuroinflammation: reducing LPS induced activation of microglia, lowering levels of pro-inflammatory factors such as IL-6, and improving diarrhea symptoms in IBS-D patients.
Optimize vagus nerve signals: enhance PFC amygdala loop function, improve emotional interpretation of vagus nerve signals, and alleviate functional abdominal pain.
Key issues in dosage form optimization
The current research and development of Cerebrolysin Sirop needs to address the following challenges:
Stability: Peptides pose a risk of enzymatic hydrolysis in the gastrointestinal tract and require nanoencapsulation or chemical modification to enhance stability.
Bioaccumulation: Low oral absorption rate, requiring the development of carrier systems with stronger penetration capabilities (such as cell penetrating peptide modification).
Safety: Long term use may induce antibody production, and IgE levels and allergic reactions need to be monitored.
Hot Tags: cerebrolysin sirop, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale